Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study
Titel:
Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study
Auteur:
Patrikidou, Anna Saieva, Calogero Lee-Ying, Richard Nuzzo, Pier Vitale Zarif, Talal El McClure, Heather Davidsohn, Matthew Eid, Marc Spinelli, Gian Paolo Catalano, Fabio Cremante, Malvina Fotia, Giuseppe Rossetti, Sabrina Valenca, Loana Vauchier, Charles Ottanelli, Carlotta Andrade, Livia Gennusa, Vincenzo Mestre, Ricardo Pereira Fornarini, Giuseppe Pignata, Sandro Procopio, Giuseppe Santini, Daniele Ravi, Praful Sweeney, Christopher Heng, Daniel De Giorgi, Ugo Fizazi, Karim Russo, Antonio Francini, Edoardo